TriMark Publications Announces the TriMark Molecular Diagnostics Conference 2008 in Boston on March 31st

Share Article

TriMark Publications, a global leader in biotechnology, healthcare and life sciences publishing, announces the TriMark Molecular Diagnostics Conference 2008 entitled: Personalized Medicine through Genomic Analysis and Molecular Diagnostics.”

Personalized Medicine through Genomic Analysis and Molecular Diagnostics

TriMark Publications (, a global leader in biotechnology, healthcare and life sciences publishing, announces the TriMark Molecular Diagnostics Conference 2008 entitled:

“Personalized Medicine through Genomic Analysis and Molecular Diagnostics”

The Conference will be held on Monday, March 31, 2008 at Harvard Medical School located at the Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston, Massachusetts, U.S.A. Registration details at

The TriMark Molecular Diagnostics 2008 Conference has been organized to provide a critical examination of the molecular diagnostics industry, as well as to provide insight from key industry leaders concerning cutting-edge molecular diagnostics technology. This conference will also provide an integral forum for leaders in molecular diagnostics, in vitro diagnostics and laboratories to share ideas, network with other delegates and advance understanding of the potential of new molecular diagnostics technologies. The agenda will include:

7:15 am – 8:15 am Registration and Continental Breakfast

8:15 am – 8:30 am Welcoming and Introductory Remarks
Joseph Dooley, Ph.D., DABCC, FACB, Editor-in-Chief, TriMark Publications, LLC

8:30 am – 9:15 am Keynote Speaker – Overview of the Medical Uses of Pharmacogenomics
Roland Valdes, Ph.D., Professor and Senior Vice-Chairman Academic Affairs and Research Director, Clinical Chemistry, University of Louisville

9:15 am – 10:00 am Bringing Molecular Diagnostics to the Clinical Laboratory
Helen Fernandes, PhD., Dept. Pathology and Lab Medicine, New Jersey School/University Hospital

10:00 am – 10:45 am Using Pharmacogentics to Improve Warfarin Dosing
Gwen McMillin, Ph.D., Assistant Professor (Clinical) Pathology, University of Utah, ARUP Laboratory

10:45 am – 11:15 am Intermission – Meet the Exhibitors

11:15 am – 12:00 pm FDA Quality System Requirements for Molecular Diagnostics
Kaiser Aziz, Ph.D., U.S. Food and Drug Administration (Retired)

12:00 pm – 1:00 pm Seated Luncheon in Dining Room

1:00 pm – 1:45 pm Linking Personalized Medicine with Genomics and Molecular Diagnostics
Graham Ligard, Ph.D., Senior Vice President of Research and Development, Nanogen

1:45 pm – 2:30 pm Presentation Name TBA
David Okrongly, Ph.D., Senior Vice President Molecular Diagnostics, Siemens Medical Solutions Diagnostics

2:30 pm – 3:15 pm The PhyzioType System for DNA-Guided Medicine: Prevention and Diagnosis of Side Effects Induced by Statins and Psychotropic Drugs
Gualberto Ruaño, M.D., Ph.D., President and CEO, Genomas, Inc. and Director of Genetics Research, Hartford Hospital

3:15 pm – 4:00 pm Intermission

4:00 pm – 4:45 pm Strategic Review of Molecular Diagnostics
Harry Glorikian, Managing Partner, Scientia Advisors

4:45 pm – 5:15 pm Business Changes in Molecular Diagnostic Testing Sector; What’s Happening and Why
Joseph Dooley, Ph.D., DABCC, FACB, Editor-in-Chief, TriMark Publications, LLC

5:15 pm – 6:00 pm Wine and Cheese

Who Should Attend:

  •     Molecular diagnostics companies.
  •     In vitro diagnostic companies.
  •     Biotechnology companies.
  •     Medical devices manufacturers.
  •     Molecular diagnostic laboratorians

Leaders from the Following Areas Will Greatly Benefit from Attending:

  •     Laboratory leaders.
  •     Hospital CFOs and CSOs.
  •     Molecular diagnostics and in vitro diagnostic companies.
  •     Business development.
  •     Strategic planning and development.
  •     Technology development.
  •     Marketing.
  •     Research and development.

Key Themes:

  •     A critical examination of key emerging technologies applicability to molecular diagnostics.
  •     Formation of successful alliances.
  •     Partnering of emerging technologies with molecular diagnostics.
  •     Transitioning from laboratory in vitro diagnostics to molecular diagnostics.
  •     The emerging role of molecular diagnostic tests in personalized medicine.
  •     The intersection of pharmacogenomics and molecular diagnostics with personalized medicine.

Questions Answered in the TriMark Conference:

  •     What will the molecular diagnostics market be worth by the end of the decade?
  •     Which market key segments will drive molecular diagnostics market growth?
  •     Which new technologies will reach the molecular diagnostics market in the next 2-3 years?
  •     How is technology innovation impacting the dynamics and ownership of the molecular diagnostics industry?
  •     How can clinical labs bring in new molecular diagnostic tests?
  •     What are the key challenges in gaining acceptance of new technologies by users, payers and regulators?
  •     How is technology innovation facilitating the transition of molecular diagnostics testing into standard healthcare practice?

Top Five Reasons To Attend the TriMark Conference:

  •     Discover the molecular diagnostics sectors with the greatest prospective growth, ensuring you can successfully align your future strategies with predicted success.
  •     Evaluate the competitive dynamics of the molecular diagnostics market and understand the changing relationship between IVD companies and the molecular diagnostics testing sector.
  •     Identify the key players in the molecular diagnostics market, recognize lucrative partnering opportunities and benchmark your strategies against the leading players.
  •     Assess opportunities and challenges faced by diagnostic companies in gaining acceptance of innovative technologies by payers, regulators and users.
  •     Understand the factors driving growth of the molecular diagnostics market.

Registration Fees for the Conference:

  •     Early-Bird Registration Fee is $750 until February 29, 2008.
  •     Standard Registration Fee is $995 on and after March 1, 2008.
  •     At-the-Door Fee $1,295 on March 31, 2008 (subject to seating availability).

Register at

About TriMark Publications, LLC
Based in New York City, TriMark Publications is a global leader in biotechnology, healthcare and life sciences publishing. For more information, please visit

Important Notice
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

TriMark Publications, LLC


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joe Dooley
Visit website